Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2365664 | 0.89 | APP (0.38) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL26306079 | 0.88 | — | — | |
| SCHEMBL23268493 | 0.85 | — | — | |
| SCHEMBL26306147 | 0.79 | APP (0.33) | APP | |
| SCHEMBL11142415 | 0.77 | PTGS1 (0.35) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL23268443 | 0.76 | APP (0.31) | APP | |
| SCHEMBL26306097 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL3489362 | 0.74 | — | — | |
| SCHEMBL20839542 | 0.74 | — | — | |
| SCHEMBL26137899 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753635-B2 | Methods and systems and related compositions for mixtures separation with a solid matrix | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-09-12 | — | — | US | claimed |
| US-11572385-B2 | Process for the preparation of concentrated liquid formulations containing biomolecules | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-02-07 | — | — | US | claimed |
| US-20220049242-A1 | METHODS AND SYSTEMS AND RELATED COMPOSITIONS FOR MIXTURES SEPARATION WITH A SOLID MATRIX | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-02-17 | — | — | US | claimed |
| US-11174477-B2 | Methods and systems and related compositions for mixtures separation with a solid matrix | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-11-16 | — | — | US | claimed |
| US-20190309016-A1 | PROCESS FOR THE PREPARATION OF HIGHLY CONCENTRATED LIQUID FORMULATIONS CONTAINING BIOMOLECULES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2019-10-10 | — | — | US | claimed |
| EP-3500588-A1 | PROCESS FOR THE PREPARATION OF HIGHLY CONCENTRATED LIQUID FORMULATIONS CONTAINING BIOMOLECULES | Boehringer Ingelheim International GmbH (DE) | 2019-06-26 | — | — | EP | claimed |
| US-20190078080-A1 | METHODS AND SYSTEMS AND RELATED COMPOSITIONS FOR MIXTURES SEPARATION WITH A SOLID MATRIX | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2019-03-14 | — | — | US | claimed |
| WO-2019050480-A1 | METHODS OF SCREENING HAIR GROWTH OR HAIR CYCLE REGULATING AGENTS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-14 | — | — | WO | claimed |
| WO-2018033482-A1 | PROCESS FOR THE PREPARATION OF HIGHLY CONCENTRATED LIQUID FORMULATIONS CONTAINING BIOMOLECULES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-22 | — | — | WO | claimed |
| WO-2013152164-A2 | SLURRY COMPOSITION AND METHOD OF USE | FERRO CORPORATION (US) | 2013-10-10 | — | — | WO | claimed |
| US-5089420-A | With an indicator dye, a hydroperoxide and a buffer; especially useful for assaying accult blood | MILES INC. (US) | 1992-02-18 | — | — | US | claimed |
| WO-1991009940-A1 | STABLE FORMULATION OF VIRAL NEURAMINIDASE | SYMEX CORP. (US) | 1991-07-11 | — | — | WO | claimed |
| EP-3496763-B1 | PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260022191-A1 | METHOD OF PREPARING AN ANTIBODY WITH THIOL GROUP SITE-SPECIFIC MODIFICATIONS AND USE OF TCEP | SUZHOU BIOREINNO BIOTECHNOLOGY LTD COMPANY (CN) | 2026-01-22 | — | — | US | disclosed |
| US-20260015433-A1 | METHOD OF PREPARING AN ANTIBODY WITH SITE-SPECIFIC MODIFICATIONS | SUZHOU BIOREINNO BIOTECHNOLOGY LTD COMPANY (CN) | 2026-01-15 | — | — | US | disclosed |
| US-20250367624-A1 | BIOPOLYMER SYNTHESIS BY METAL-POLYMERIC PARTICLES | LENOVA SINGAPORE PTE LTD (SG) | 2025-12-04 | — | — | US | disclosed |
| EP-0328413-A2 | Sodium decyl sulfate wash solution, test kit and method for the determination of an immunological ligand | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1989-08-16 | — | — | EP | disclosed |
| EP-0328388-A2 | Wash solution, test kit and method for the determination of an immunological ligand | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1989-08-16 | — | — | EP | disclosed |
| US-4795712-A | USING 1,2-BIS/0-AMINOARYLOXY)ETHANE-N,N,N*,N*-TETRAACETIC ACID DERIVATIVE | EASTMAN KODAK COMPANY (US) | 1989-01-03 | — | — | US | disclosed |
| EP-0286402-A2 | Calcium complexing dyes and their use in analytical compositions, elements and methods | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015433-A1 | METHOD OF PREPARING AN ANTIBODY WITH SITE-SPECIFIC MODIFICATIONS | BCDIN3D, BTD, DCTD | PTGS1 4638/4885PDE4A 3600/4885LMNA 4713/4885 |
| US-20260022191-A1 | METHOD OF PREPARING AN ANTIBODY WITH THIOL GROUP SITE-SPECIFIC MODIFICATIONS AND USE OF TCEP | PTMS, TMT1A, PCTP | PTGS1 4285/4885PDE4A 4599/4885LMNA 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.